What the FDA labels say about taking them together
Nateglinide and teriflunomide
Teriflunomide's FDA label of February 20, 2026 names nateglinide in its drug interactions section; the nateglinide label PlainMeds reads does not name teriflunomide. The teriflunomide label: “For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family, especially HMG-Co reductase inhibitors, consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of …”
Check it at the source: the nateglinide FDA label on DailyMed (effective February 24, 2025, Strides Pharma Science Limited); the teriflunomide FDA label on DailyMed (effective February 20, 2026, Genzyme Corporation).
What does the nateglinide label say about teriflunomide?
Nateglinide's label (effective February 24, 2025) does not name teriflunomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nateglinide), Strides Pharma Science Limited, effective February 24, 2025 (SPL set 0ccf9b07-3c21-482d-abeb-a06ceb482c7b), via openFDA; the full label on DailyMed
What does the teriflunomide label say about nateglinide?
Teriflunomide label, drug interactionsFor other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Aubagio), NDA202992 (Sanofi Aventis Us), as published by Genzyme Corporation, effective February 20, 2026 (SPL set 4650d12c-b9c8-4525-b07f-a2d773eca155), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nateglinide | Teriflunomide | |
|---|---|---|
| Labeled for | Type 2 diabetes | Multiple sclerosis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.179 per tablet 60 mg tablet | $0.233 per tablet 14 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once